Literature DB >> 26710976

Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer.

Christopher D Heinen1.   

Abstract

We have currently entered a genomic era of cancer research which may soon lead to a genomic era of cancer treatment. Patient DNA sequencing information may lead to a personalized approach to managing an individual's cancer as well as future cancer risk. The success of this approach, however, begins not necessarily in the clinician's office, but rather at the laboratory bench of the basic scientist. The basic scientist plays a critical role since the DNA sequencing information is of limited use unless one knows the function of the gene that is altered and the manner by which a sequence alteration affects that function. The role of basic science research in aiding the clinical management of a disease is perhaps best exemplified by considering the case of Lynch syndrome, a hereditary disease that predisposes patients to colorectal and other cancers. This review will examine how the diagnosis, treatment and even prevention of Lynch syndrome-associated cancers has benefitted from extensive basic science research on the DNA mismatch repair genes whose alteration underlies this condition.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Colorectal cancer; Lynch syndrome; Microsatellite instability; Mismatch repair; Personalized medicine

Mesh:

Year:  2015        PMID: 26710976      PMCID: PMC4740212          DOI: 10.1016/j.dnarep.2015.11.025

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  125 in total

1.  Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein.

Authors:  Saara Ollila; Laura Sarantaus; Reetta Kariola; Philip Chan; Heather Hampel; Elke Holinski-Feder; Finlay Macrae; Maija Kohonen-Corish; Anne-Marie Gerdes; Päivi Peltomäki; Elisabeth Mangold; Albert de la Chapelle; Marc Greenblatt; Minna Nyström
Journal:  Gastroenterology       Date:  2006-08-22       Impact factor: 22.682

2.  Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.

Authors:  G Samimi; D Fink; N M Varki; A Husain; W J Hoskins; D S Alberts; S B Howell
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

3.  A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants.

Authors:  Mark Drost; José B M Zonneveld; Sandrine van Hees; Lene Juel Rasmussen; Robert M W Hofstra; Niels de Wind
Journal:  Hum Mutat       Date:  2011-12-29       Impact factor: 4.878

Review 4.  CpG island methylator phenotype in cancer.

Authors:  Jean-Pierre Issa
Journal:  Nat Rev Cancer       Date:  2004-12       Impact factor: 60.716

5.  DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1.

Authors:  Sarah A Martin; Nuala McCabe; Michelle Mullarkey; Robert Cummins; Darren J Burgess; Yusaku Nakabeppu; Sugako Oka; Elaine Kay; Christopher J Lord; Alan Ashworth
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

6.  Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1.

Authors:  Petr Cejka; Lovorka Stojic; Nina Mojas; Anna Marie Russell; Karl Heinimann; Elda Cannavó; Massimiliano di Pietro; Giancarlo Marra; Josef Jiricny
Journal:  EMBO J       Date:  2003-05-01       Impact factor: 11.598

7.  Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin.

Authors:  D Fink; S Nebel; P S Norris; R N Baergen; S P Wilczynski; M J Costa; M Haas; S A Cannistra; S B Howell
Journal:  Int J Cancer       Date:  1998-08-31       Impact factor: 7.396

Review 8.  O6-methylguanine-DNA methyltransferase in the defense against N-nitroso compounds and colorectal cancer.

Authors:  Jörg Fahrer; Bernd Kaina
Journal:  Carcinogenesis       Date:  2013-08-08       Impact factor: 4.944

9.  Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.

Authors:  H A Tawbi; J H Beumer; A A Tarhini; S Moschos; S C Buch; M J Egorin; Y Lin; S Christner; J M Kirkwood
Journal:  Ann Oncol       Date:  2012-11-21       Impact factor: 32.976

10.  Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2.

Authors:  Sarah A Martin; Afshan McCarthy; Louise J Barber; Darren J Burgess; Suzanne Parry; Christopher J Lord; Alan Ashworth
Journal:  EMBO Mol Med       Date:  2009-09       Impact factor: 12.137

View more
  25 in total

1.  Functional interrogation of Lynch syndrome-associated MSH2 missense variants via CRISPR-Cas9 gene editing in human embryonic stem cells.

Authors:  Abhijit Rath; Akriti Mishra; Victoria Duque Ferreira; Chaoran Hu; Gregory Omerza; Kevin Kelly; Andrew Hesse; Honey V Reddi; James P Grady; Christopher D Heinen
Journal:  Hum Mutat       Date:  2019-08-17       Impact factor: 4.878

2.  Recurrent mismatch binding by MutS mobile clamps on DNA localizes repair complexes nearby.

Authors:  Pengyu Hao; Sharonda J LeBlanc; Brandon C Case; Timothy C Elston; Manju M Hingorani; Dorothy A Erie; Keith R Weninger
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

3.  The Devil is in the details for DNA mismatch repair.

Authors:  Peggy Hsieh; Yongliang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-29       Impact factor: 11.205

Review 4.  Break-induced replication links microsatellite expansion to complex genome rearrangements.

Authors:  Michael Leffak
Journal:  Bioessays       Date:  2017-06-16       Impact factor: 4.345

Review 5.  Eukaryotic Mismatch Repair in Relation to DNA Replication.

Authors:  Thomas A Kunkel; Dorothy A Erie
Journal:  Annu Rev Genet       Date:  2015       Impact factor: 16.830

6.  Single-Molecule FRET to Measure Conformational Dynamics of DNA Mismatch Repair Proteins.

Authors:  J W Gauer; S LeBlanc; P Hao; R Qiu; B C Case; M Sakato; M M Hingorani; D A Erie; K R Weninger
Journal:  Methods Enzymol       Date:  2016-10-05       Impact factor: 1.600

7.  Elucidating the clinical significance of two PMS2 missense variants coexisting in a family fulfilling hereditary cancer criteria.

Authors:  Maribel González-Acosta; Jesús Del Valle; Matilde Navarro; Bryony A Thompson; Sílvia Iglesias; Xavier Sanjuan; María José Paúles; Natàlia Padilla; Anna Fernández; Raquel Cuesta; Àlex Teulé; Guido Plotz; Juan Cadiñanos; Xavier de la Cruz; Francesc Balaguer; Conxi Lázaro; Marta Pineda; Gabriel Capellá
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

Review 8.  Endonuclease activities of MutLα and its homologs in DNA mismatch repair.

Authors:  Lyudmila Y Kadyrova; Farid A Kadyrov
Journal:  DNA Repair (Amst)       Date:  2015-12-02

Review 9.  The changing landscape of Lynch syndrome due to PMS2 mutations.

Authors:  J Blount; A Prakash
Journal:  Clin Genet       Date:  2018-03-15       Impact factor: 4.438

Review 10.  Translational Research in Familial Colorectal Cancer Syndromes.

Authors:  Molly M Ford
Journal:  Clin Colon Rectal Surg       Date:  2018-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.